Explore. Learn. Join the conversation.

Working Group on New TB Drugs

Stop TB Partnership

Community Engagement through Drama

gillian-blackb

Dr. Gill Black is the co-founder and Director of Health and Welfare at The Sustainable Livelihoods Foundation (SLF). In this inteview, we discuss with Dr. Black one of SLF’s groundbreaking projects that uses drama to engage local communities around issues related to TB and HIV/AIDS.

12 Oct 2011

Winstone’s Voice

As has been widely reported, we lost Winstone Zulu, a tireless advocate for TB/HIV. Chief among his gifts was the ability to speak with passion about his subject, finding the precise balance between hard facts, personal history, and an inspiring call to action.

21 Jun 2011
by Christopher Cooper

Posted in Early Drug Development, TB Drug Development

TB R&D Weekly Update: Potential Use of Polyether Ionophores Against TB

polyether ionophores

During this week’s TB R&D Weekly Update, we explore the potential of polyether ionophores as anti-tuberculosis agents in an article published in 2009 by Kevin, et al. Links to additional TB R&D News are included.

Call to Action–Save a million lives by 2015

time to act

On June 6, 2011, the Stop TB Partnership launched the initiative Time to Act–Save a Million Lives by 2015 at the UN Headquarters at a reception hosted by Ray Chambers, the UN Secretary-General’s Special Envoy for Malaria and UN MDG Advocate. If you would like to respond to this call to action, visit www.action.org.

Interview with Dr. Mark Cotton – Part Two

mark-cotton-interview

Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years. This is part two of our interview with him.

Interview with Dr. Mark Cotton – Part One

mark-cotton-interview

Dr. Mark Cotton is Director of Children’s Infectious Diseases Clinical Research Unit (KID-CRU) at University of Stellenbosch in Cape Town, South Africa. Pediatric TB has emerged as a broad priority only in more recent years, though the University of Stellenbosch / Tygerberg Hospital team has been focusing on it for more than 20 years.

TB R&D Weekly Update: Combined Isoniazid and Antiretroviral Therapy Protects HIV-infected Children

thorax

In this week’s TB R&D update, the focus is on pediatrics and tuberculosis with several studies published on the subject. Frigati, et al., wanted to determine if isoniazid preventive therapy (IPT) combine with antiretroviral therapy (ART) would reduce TB in HIV-infected children. The article is published online ahead of print this month in Thorax and is entitled “The impact of isoniazid preventive therapy and antiretroviral therapy on tuberculosis in children infected with HIV in a high tuberculosis incidence setting.” Also, links to additional news in TB R&D are included.

New Report on Drugs for Drug-resistant TB

cover msf union report

The Médecins Sans Frontières and The Union will release on World TB Day a new report entitled “DR-TB drugs under the microscope” outlining drugs currently available to treat drug-resistant tuberculosis (DR-TB) including product information, sources of the drug, quality status, and price.

1 Feb 2011

TB R&D Weekly Update: Study of Mother-to-Child Transmission of HIV Shows TB to be Risk Factor

JID cover

In this week’s TB R&D update, we look at TB as a risk factor for mother-to-child transmission of HIV. The research is published in the February issue of the Journal of Infectious Diseases and is entitled “Maternal tuberculosis: a risk factor for mother-to-child transmission of human immunodeficiency virus.” Also, links to additional news in TB R&D are included.

6 Jan 2011

Interview with Dr. Anneke Hesseling – Part One

anneke-150

An interview with Dr. Anneke Hesseling, the Director of the Paediatric TB Research Program at the Desmond Tutu TB Centre at Stellenbosch University in Cape Town, South Africa.